Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3-dependent sensitization

Alexandra Jurczak, Lauriane Delay, Julie Barbier, Nils Simon, Emerson Krock, Katalin Sandor, Nilesh M. Agalave, Resti Rudjito, Gustaf Wigerblad, Katarzyna Rogóż, Arnaud Briat, Elisabeth Miot-Noirault, Arisai Martinez-Martinez, Dieter Brömme, Caroline Grönwall, Vivianne Malmström, Lars Klareskog, Spiro Khoury, Thierry Ferreira, Bonnie LabrumEmmanuel Deval, Juan Miguel Jiménez-Andrade, Fabien Marchand, Camilla I. Svensson

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Several bone conditions, eg, bone cancer, osteoporosis, and rheumatoid arthritis (RA), are associated with a risk of developing persistent pain. Increased osteoclast activity is often the hallmark of these bony pathologies and not only leads to bone remodeling but is also a source of pronociceptive factors that sensitize the bone-innervating nociceptors. Although historically bone loss in RA has been believed to be a consequence of inflammation, both bone erosion and pain can occur years before the symptom onset. Here, we have addressed the disconnection between inflammation, pain, and bone erosion by using a combination of 2 monoclonal antibodies isolated from B cells of patients with RA. We have found that mice injected with B02/B09 monoclonal antibodies (mAbs) developed a long-lasting mechanical hypersensitivity that was accompanied by bone erosion in the absence of joint edema or synovitis. Intriguingly, we have noted a lack of analgesic effect of naproxen and a moderate elevation of few inflammatory factors in the ankle joints suggesting that B02/B09-induced pain-like behavior does not depend on inflammatory processes. By contrast, we found that inhibiting osteoclast activity and acid-sensing ion channel 3 signaling prevented the development of B02/B09-mediated mechanical hypersensitivity. Moreover, we have identified secretory phospholipase A2 and lysophosphatidylcholine 16:0 as critical components of B02/B09-induced pain-like behavior and shown that treatment with a secretory phospholipase A2 inhibitor reversed B02/B09-induced mechanical hypersensitivity and bone erosion. Taken together, our study suggests a potential link between bone erosion and pain in a state of subclinical inflammation and offers a step forward in understanding the mechanisms of bone pain in diseases such as RA.

Original languageEnglish
Pages (from-to)1542-1559
Number of pages18
Issue number8
StatePublished - 1 Aug 2022
Externally publishedYes


  • ASIC3
  • Autoantibodies
  • Bone
  • LPC
  • Lipids
  • Osteoclasts
  • Pain
  • Rheumatoid arthritis
  • sPLA


Dive into the research topics of 'Antibody-induced pain-like behavior and bone erosion: links to subclinical inflammation, osteoclast activity, and acid-sensing ion channel 3-dependent sensitization'. Together they form a unique fingerprint.

Cite this